"Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. [PubChem]"@en . . "Capreomycin"@en . . . . "When a 1\u2013g dose of capreomycin was given intramuscularly to normal volunteers, 52% was excreted in the urine within 12 hours."@en . . . . . . " "@en . . . . . "Enteric bacteria and other eubacteria"@en . . . . . . . . . . . . . . "Used in the treatment of tuberculosis in combination with other drugs."@en . . . . . . . . . . . "11003-38-6"@en . "Not absorbed in significant quantities from the gastrointestinal tract and must be administered parenterally."@en . . "Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins. These proteins are necessary for the bacteria's survival. Therefore the production of these abnormal proteins is ultimately fatal to the bacteria."@en . . "Hypokalemia, hypocalcemia, hypomagnesemia, and an electrolyte disturbance resembling Bartter's syndrome have been reported to occur in patients with capreomycin toxicity. The subcutaneous median lethal dose (LD₅₀) in mice was 514 mg/kg."@en . . . . . . . "approved"@en . . . "Michael George Thomas, Elizabeth Anne Felnagle, Michelle Renee Rondon, Andrew David Berti, \"Heterologous Production of Capreomycin and Generation of New Capreomycin Derivatives Through Metabolic Engineering.\" U.S. Patent US20090104658, issued April 23, 2009."@en .